Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Edward Nash has reaffirmed a Buy rating on Corcept Therapeutics (NASDAQ:CORT) and increased the price target from $37 to $38.
December 13, 2023 | 4:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst Edward Nash maintains a Buy rating on Corcept Therapeutics and raises the price target from $37 to $38, indicating a positive outlook on the stock.
The increase in price target by Canaccord Genuity suggests a bullish stance on Corcept Therapeutics, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100